Alexion to Pick Goldman to Advise on Roche Offer?

July 30 (Bloomberg) -- Alexion Pharmaceuticals, the drugmaker whose blood-disease treatment is among the world’s most expensive medicines, engaged Goldman Sachs as an adviser as it prepares for a possible takeover offer from Roche, said people with knowledge of the matter. Cristina Alesci reports on Bloomberg Television's "Money Moves." (Source: Bloomberg)

The Natural Catastrophes Hurting Swiss Re's Profits
53:07 - Swiss Re AG, the world’s biggest reinsurer, said profit fell in the second-quarter as the company paid more for catastrophe claims including earthquakes in Japan and forest fires in Canada. Net income declined to $637 million from $820 million a year earlier, the Zurich-based company said in a statement on Friday. That beat the $605 million average estimate of nine analysts in a Bloomberg survey. Chief Financial Officer David Cole discusses with Bloomberg's Francine Lacqua on "The Pulse."
  • Ceccatelli: Italian Banks Quite Weak on Average
  • Redeker: There Is Still Room to the Downside
  • Did Kuroda's Radical Policy Knowingly Disappoint?